Medications

Eight-week bedaquiline-linezolid noninferior for TB

A strategy of eight weeks of bedaquiline-linezolid is noninferior to a standard regimen for tuberculosis, according to a study published online Feb. 20 in the New England Journal of Medicine to coincide with the annual Conference ...

Oncology & Cancer

Risk of side effects from cancer immunotherapy linked to genetics

Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, ...

page 8 from 26